QR kȏd

Change of glucometabolic activity per PSMA expression predicts survival in mCRPC patients non-responding to PSMA radioligand therapy: introducing a novel dual imaging biomarker

PurposeThe value of [18F]fluorodeoxyglucose ([18F]FDG) PET/CT in monitoring prostate-specific membrane antigen (PSMA) targeted radioligand therapy (RLT) is still unclear. The aim of this study was to identify appropriate prognostic dynamic parameters derived from baseline and follow-up [18F]FDG and...

Cijeli opis

Spremljeno u:
Glavni autori: Caroline Burgard, Jakob Engler, Arne Blickle, Mark Bartholomä, Stephan Maus, Andrea Schaefer-Schuler, Fadi Khreish, Samer Ezziddin, Florian Rosar
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2024-01-01
Serija:Frontiers in Medicine
Teme:
PSMA—prostate-specific membrane antigen
PET/CT
radioligand therapy
prostate cancer
dual imaging
Online pristup:https://www.frontiersin.org/articles/10.3389/fmed.2023.1339160/full
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Slični predmeti